Kai Tatsuya, Kanamasa Ken
Department of Vascular and Geriatric Medicine, Kinki University School of Medicine, Osaka, Japan.
Arzneimittelforschung. 2009;59(9):445-50. doi: 10.1055/s-0031-1296423.
The plasma level of adiponectin (CAS 1070484-33-1), known as an anti-atherogenic adipocytokine, inversely correlates with the progression of atherosclerosis. The reported effects of statins on the serum level of adiponectin include significant increases in the adiponectin levels caused by pravastatin (CAS 81131-70-6). In this study, increasing the dosage of pravastatin was investigated to determine whether it had a clearly favorable effect on the adiponectin level in hypercholesterolemic patients. A total of 26 mild hypercholesterolemic and hypertensive patients were enrolled in this study. The patients were initially treated with pravastatin 10 mg/day for 6 months or more, and then increased to pravastatin 20 mg/day. Serum adiponectin, cholesterol fractionated components, and lipoprotein components were evaluated after 6 months. Increasing the dose of pravastatin from 10 to 20 mg/day caused the low-density lipoprotein cholesterol levels to decrease (from 130 to 104 mg/dL, p < 0.001), and thereafter the serum adiponectin levels, particularly the high-molecular-weight adiponectin levels significantly increased (from 10.9 to 12.6 microg/mL, p = 0.022; from 6.6 to 7.6 microg/mL, p = 0.022, respectively). Pravastatin increased the serum adiponectin level after increasing the dosage from 10 to 20 mg/day. It remains possible, however, that the difference was due not only to pharmacologic effects, but also to other specific characteristics such as the subject characteristics, viz.; race, body size, high-density lipoprotein cholesterol, etc.
脂联素（CAS 1070484 - 33 - 1）是一种具有抗动脉粥样硬化作用的脂肪细胞因子，其血浆水平与动脉粥样硬化的进展呈负相关。他汀类药物对脂联素血清水平的报道作用包括普伐他汀（CAS 81131 - 70 - 6）可显著提高脂联素水平。在本研究中，对增加普伐他汀剂量进行了研究，以确定其对高胆固醇血症患者的脂联素水平是否具有明显的有益作用。本研究共纳入26例轻度高胆固醇血症和高血压患者。患者最初接受10 mg/天的普伐他汀治疗6个月或更长时间，然后增加至20 mg/天的普伐他汀。6个月后评估血清脂联素、胆固醇分级成分和脂蛋白成分。将普伐他汀剂量从10 mg/天增加至20 mg/天导致低密度脂蛋白胆固醇水平降低（从130降至104 mg/dL，p < 0.001），此后血清脂联素水平，特别是高分子量脂联素水平显著升高（分别从10.9升至12.6 μg/mL，p = 0.022；从6.6升至7.6 μg/mL，p = 0.022）。普伐他汀在剂量从10 mg/天增加至20 mg/天后提高了血清脂联素水平。然而，差异不仅可能归因于药理作用，还可能归因于其他特定特征，如受试者特征，即种族、体型、高密度脂蛋白胆固醇等。
